3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Breast
2
Tumor-Agnostic
1
Myeloid
1
Gastrointestinal
1
Classical hematology
1
CNS
1
Conditions
Thrombocytopenia
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Interventions
fludarabine
63
Cyclophosphamide
63
venetoclax
57
Azacitidine
52
fludarabine phosphate
50
Specimen Handling
43
Whole-Body Irradiation
40
Mycophenolic Acid
37
ruxolitinib
36
Tacrolimus
35
Melphalan
32
Busulfan
32
Biopsy
31
Cytarabine
30
Stem Cell Transplantation
27
Decitabine
27
Granulocyte Colony-Stimulating Factor
21
asciminib
19
decitabine and cedazuridine drug combination
18
Sirolimus
18
Peripheral Blood Stem Cell Transplantation
18
Injections
18
Thiotepa
17
Filgrastim
17
nilotinib
15
X-Rays
14
Methotrexate
14
Cyclosporine
14
Imatinib Mesylate
13
Magnetic Resonance Spectroscopy
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Tranexamic Acid
×
Myeloid
×
1 year
×
Clear all
NCT06599762
2026-04-22
MYELO-CAN:TXA
University of Manitoba
Phase 2
Recruiting
75 enrolled